menu
    • menu
    [{"orgOrder":0,"company":"Lambda Therapeutic Research Ltd","sponsor":"Ayana Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Lambda Therapeutic Research Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Lambda Therapeutic Research Ltd","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lambda Therapeutic Research Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lambda Therapeutic Research Ltd \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Lambda Therapeutic Research Ltd \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Lambda Therapeutic Research Ltd","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"INTP5","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lambda Therapeutic Research Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Lambda Therapeutic Research Ltd","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"INTP5","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lambda Therapeutic Research Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Lambda Therapeutic Research Ltd","sponsor":"Lambda Therapeutic Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Mulberry Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Lambda Therapeutic Research Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Lambda Therapeutic Research Ltd","sponsor":"Lambda Therapeutic Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Mulberry Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Lambda Therapeutic Research Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Lambda Therapeutic Research Ltd \/ Lambda Therapeutic Research Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Lambda Therapeutic Research Ltd

    Menu

    Lambda Therapeutic Research Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

                            Details : Denosumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mulberry Extract

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Unilever R&D

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response

                            Details : Mulberry Extract is a plant extract/herbal drug, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 06, 2020

                            Lead Product(s) : Mulberry Extract

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Unilever R&D

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mulberry Extract,Boiled Rice

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Unilever R&D

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Response Study of a Natural Extract for Reducing Post Prandial Blood Glucose

                            Details : Mulberry Extract is a plant extract/herbal drug, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 05, 2020

                            Lead Product(s) : Mulberry Extract,Boiled Rice

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Unilever R&D

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INTP5,Pegfilgrastim

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceut...

                            Details : INTP5 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 10, 2019

                            Lead Product(s) : INTP5,Pegfilgrastim

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INTP5

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharma...

                            Details : INTP5 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 10, 2019

                            Lead Product(s) : INTP5

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed

                            Lambda Therapeutic Research Ltd

                            India arrow
                            IPPE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Ayana Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

                            Details : Doxorubicin HCl is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 24, 2018

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Ayana Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.